Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seoul National University Hospital
With
Korea Otsuka Pharmaceutical Co., Ltd.
* reduced treatment adherence due to metabolic side effects
* suggested advantages of aripiprazole in metabolic profile over other antipsychotics or mood stabilizers
* randomized trial of switch from previous drugs to aripiprazole
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
patients with bipolar disorders (I, II, NOS) diagnosed with DSM-IV criteria
age between 18 and 65
Decisional capacity is adequate to provide informed consent or has an authorized appropriate surrogate decision maker. in a syndromal remission state at least for 2 months : CGI - BP ≤ 3
patients who have exhibited a clinically significant increase in body weight after starting the administration of their current antipsychotic (ie \>7% weight gain)
You may not be if
diagnosis of eating disorder, substance abuse, and psychotic disorder
history of neurological and medical illness
pregnant or breast feeding women
Clareo Health | Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders
